![](/img/cover-not-exists.png)
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma
Lossos, Izidore S., Hosein, Peter J., Morgensztern, Daniel, Coleman, Francine, Escalón, Maricer P., Byrne, Gerald E., Rosenblatt, Joseph D., Walker, Gail R.Volume:
51
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.3109/10428190903518345
Date:
March, 2010
File:
PDF, 467 KB
english, 2010